Notification That Annual Report Will Be Submitted Late (nt 10-k)
April 01 2022 - 06:04AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[X] Form 10-K |
[ ] Form 20-F |
[ ] Form 11-K |
[ ] Form 10-Q |
[ ] Form 10-D |
[ ] Form N-SAR |
|
|
|
|
For Period Ended: December 31, 2021
|
|
|
|
|
|
|
[ ] Transition Report on Form 10-K |
|
|
|
[ ] Transition Report on Form 10-Q |
|
|
|
For the Transition Period Ended:
__________________________ |
Nothing in this Form shall be construed to imply that the
Commission has verified any information contained
herein.
Part I - Registrant Information
Full Name of Registrant: CV Sciences, Inc.
Former Name if Applicable: N/A
Address of Principal Executive Office (Street and
Number)
10070 Barnes Canyon Road
San Diego, CA 92121
Part II - Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
|
|
|
|
|
|
|
|
|
[X] |
(a) |
The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense; |
|
|
|
|
|
|
|
|
|
|
|
|
[X] |
(b) |
The subject annual report, semi-annual report, or transition report
or portion thereof will be filed on or before the fifteenth
calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form l0-Q or portion
thereof will be filed on or before the fifth calendar day following
the prescribed due date; and |
|
|
|
[ ] |
(c) |
The accountant’s statement or other exhibit required by Rule
12b-25(c) has been attached if applicable. |
Part III - Narrative
State below in reasonable detail the reasons why the Form 10-K,
20-F, 11-K, 10-Q, or N-SAR, or the transition report or portion
thereof could not be filed within the prescribed time
period.
The Company is unable to file its Annual Report on Form 10-K for
the year ended December 31, 2021, within the prescribed time period
without unreasonable effort or expense. The Company requires
additional time to finalize its financial statements to be filed as
part of the 2021 Form 10-K.
The additional time is required for, among other things, to
incorporate its most recent subsequent events into its Form 10-K,
which include two significant financings both closed within a week
of the filing deadline, and work with its external auditors, which
were just recently changed in December 2021, to ensure all related
audit procedures have been performed. The Company currently expects
to file the 2021 Form 10-K on or before April 15, 2022, the
prescribed due date under the fifteen calendar day extension period
provided under Rule 12b-25.
Part IV - Other Information
|
|
|
|
|
|
|
|
|
|
(1) |
Name and telephone number of person to contact in regard to this
notification |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Joseph D. Dowling |
|
619 |
|
876-4309 |
(Name) |
|
(Area Code) |
|
(Telephone Number) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) |
Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding l2
months (or for such shorter period that the registrant was required
to file such reports) been filed? If answer is no, identify
report(s). |
|
[X] Yes |
[ ] No |
|
|
|
|
|
|
|
(3) |
Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the
subject report or portion thereof? |
|
[ ] Yes |
[X] No |
|
|
|
|
|
|
|
|
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be
made. |
|
|
|
CV Sciences, Inc.
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: March 31, 2022 |
CV Sciences, Inc. |
|
|
|
|
By: |
/s/ Joseph D. Dowling |
|
|
Joseph D. Dowling |
|
|
Chief Executive Officer |
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From May 2022 to Jun 2022
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From Jun 2021 to Jun 2022